The story of modern drug safety legislation begins with a sweet taste and a devastating consequence. The Sulfanilamide Disaster of 1937 stands as a grim monument to the catastrophic failure of drug regulation, yet decades later, the same toxic culprit—Diethylene Glycol (DEG)—continues to claim lives around the world.

This recurrence raises a chilling question central to pharmacovigilance: Have we truly learned from history?.

The Original Poison: “Taste of Raspberries, Taste of Death”

In the summer of 1937, the S.E. Massengill Co. sought to create a liquid form of the antibiotic drug Sulfanilamide. Their chief chemist, Harold Cole Watkins, found that the drug dissolved readily in Diethylene Glycol (DEG), a chemical normally used as an antifreeze. The company’s lab tested the new formulation—branded as “Elixir Sulfanilamide”—for flavor and appearance, finding it satisfactory. It was described as a sweet, raspberry-flavored medicine. Crucially, it was not tested for toxicity.

The results were catastrophic:

• Over 100 people across 15 states died, many of them children being treated for sore throats.

• Victims suffered intense pain, exhibiting symptoms characteristic of kidney failure, including nausea, vomiting, severe abdominal pain, and stupor.

• Watkins, the chemist, committed suicide after learning of the drug’s lethal effects.

At the time, federal law did not require safety studies on new drugs; selling a toxic product was not illegal. The FDA was forced to seize the drug on the technical charge of misbranding: calling it an “Elixir” (implying an alcoholic solution) when it was, in fact, a DEG solution containing no alcohol.

This inadequacy in the law dramatically hastened the enactment of the Federal Food, Drug, and Cosmetic Act of 1938, which finally mandated that manufacturers must demonstrate a drug’s safety before marketing.

The Global Failure: DEG Poisoning in the Modern Era

Despite the lessons of 1937, DEG and its chemical cousin, Ethylene Glycol (EG), continue to be used as toxic adulterants in pharmaceuticals, leading to mass poisoning incidents worldwide.

Furthermore, the risk extends beyond medicines. DEG has been found in everyday products like toothpaste (leading to product bans and recalls in Australia, Canada, and New Zealand) and has caused poisoning linked to beer in Brazil.

The Pharmacovigilance Crisis: Why India Cannot Stop DEG Deaths

Recent tragedies in India, including deaths in Jammu (2020) and a recent mass poisoning in Chhindwara, Madhya Pradesh, underscore profound systemic failures in drug regulation and pharmacovigilance.

The core issue remains adulteration: DEG is a cheaper, sweet, viscous substitute for pharmaceutical-grade glycerin and finds its way into liquid medicines. While regulations mandate that manufacturers test raw materials like glycerin, the enforcement is weak.

Key gaps that perpetuate these disasters include:

• Weak Enforcement and Inspection Gaps: Despite official standards like Good Manufacturing Practices (GMP), inspections are often infrequent, revealing egregious violations such as unhygienic conditions, using contaminated water, and a complete absence of quality checks for toxins like DEG and EG.

• Knee-Jerk Responses: Regulatory action, such as license cancellation (e.g., Marion Biotech), is often a temporary response to public outcry and can be easily rolled back, allowing repeat offenders to continue operations.

• Failure of Adverse Event Reporting: When clusters of DEG poisoning symptoms (unexplained acute renal failure, vomiting, abdominal pain) appear, the healthcare system and doctors repeatedly fail to consider DEG toxicity and trigger a prompt alert.

• Ineffective Product Recall: In India, product recalls are frequently left to manufacturers, leading to poor documentation and distribution tracing. This results in toxic medicine remaining on the shelves and causing further deaths, as seen in the 2020 Coldbest-PC case.

• Irrational Drug Market: The prevalence of highly profitable, often irrational, Fixed Dose Combination (FDC) cough syrups, which are simple to manufacture, attracts small and medium enterprises with lax standards, further complicating the oversight challenge.

• Regulatory Opacity: The drug regulatory system has been criticized for repeatedly failing to ensure drug safety and actively fighting transparency and public scrutiny.

The Sulfanilamide Disaster of 1937 was a failure of pre-market drug testing. The recurring DEG and EG tragedies of today are a failure of ongoing pharmacovigilance, quality control, and regulatory accountability. The lesson remains unchanged: the price of a safe medicine supply is eternal vigilance.